Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from ...
The global tissue engineered skin substitute market is expected to reach a value of USD 2.4 billion in 2024, with projections indicating a growth to USD 3.5 billion by 2034. The market is anticipated ...
FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of ...